ClinicalTrials.gg
Not yet recruitingNCT06509074β-TakoUpdated Aug 26, 2024

Beta-Blockers in Takotsubo Syndrome Study

A Phase 4 interventional study of Beta blocker in Takotsubo Cardiomyopathy, Beta-blockers and Echocardiography, sponsored by Spanish Society of Cardiology. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Spanish Society of Cardiology · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies will be performed. The β-Tako trial will inform treatment decisions in this uniquely challenging clinical entity.

Read the detailed description

Takotsubo syndrome (TTS) is a cardiac condition mimicking acute coronary syndrome (ACS), characterized by transient left ventricular (LV) dysfunction in the presence of normal coronary arteries. Its etiology remains unknown but reversible microvascular dysfunction secondary to an adrenergic surge appears implicated. Treatment is empiric although in clinical practice most patients receive beta-blockers (BB). The Beta-blockers in TTS (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of BB in TTS patients. TTS diagnosis will be confirmed by invasive coronary angiography and serial echocardiographic studies. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days, analyzed in an independent corelab. Changes in LV ejection fraction and global longitudinal strain will be also evaluated. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies (clinical, imaging, biomarkers, pharmacogenetic, mRNAs, quality of life) will be performed. The β-Tako trial will generate valuable scientific evidence to address unmet clinical needs and inform clinical and treatment decisions in this uniquely challenging clinical entity.

02

Conditions studied

  • Takotsubo Cardiomyopathy
  • Beta-blockers
  • Echocardiography
  • Left Ventricular Function

Keywords

  • Takotsubo Cardiomyopathy
  • beta-blockers
  • echocardiography
  • left ventricular function
  • acute myocardial infarction
  • acute coronary syndrome
  • coronary angiography
  • Normal coronary arteries
  • Heart failure
  • stress
03

In context

Takotsubo Cardiomyopathy

63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.

This study's planned enrollment of 200 is above the median of 65 across 24 interventional studies indexed under Takotsubo Cardiomyopathy.

Browse Takotsubo Cardiomyopathy studies →

Lead sponsor

Spanish Society of Cardiology is the lead sponsor of 23 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by invasive coronary angiography

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed of TTS > 48 hours before.
  • Persistent ccardiogenic shock or severe hemodynamic instability
  • Persistent severe (>30 mmHg) intraventricular gradient
  • Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD
  • Patients already receiving treatment with betablockers (*)
  • Absolute /indication for beta-blockers (**)
  • Poor echocardiographic window
  • Pregnant or breastfeeding women.
  • Participation in another clinical trial.

(*) Betablockers at a therapeutic dose at the time of symptom´s onset. (**) Close monitoring required in patients with hypotension, bradycardia or cQT interval prolongation

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Beta-blockers

    Beta-blockers with alpha or NO activity will be used. Dosage according to responsible physician and current clinical practice

    Drug: Beta blocker

  • No intervention
    No beta-blockers

    No beta-blockers

Interventions

  • DrugBeta blockersStudies of Beta blockersBeta blockers pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pragmatic design. Any beta-blocker with alpha or NO activity may be used

    Also known as: Other medications according to local clinical practice protocols and current guidelines

06

What researchers measure

Primary outcomes

  1. Wall motion score index

    Wall motion score index by echocardiography to assess recovery of left ventricular function Wall motion score index (WMSI) ranges from 1 to 4 (1 is normal and 4 worse)

    Time frame: 7 days

Secondary outcomes

  1. Left ventricular ejection fraction

    Left ventricular ejection fraction by echocardiography to assess recovery of left ventricular function

    Time frame: 7 days

  2. Global longitudinal strain

    Global longitudinal strain by echocardiography to assess recovery of left ventricular function

    Time frame: 7 days

  3. Delta (Change) in: wall motion score index, left ventricular ejection fraction, global longitudinal strain

    Changes in LV function by imaging

    Time frame: 7 days

  4. Delta (Change) in: wall motion score index, left ventricular ejection fraction, global longitudinal strain

    Changes in LV function by imaging

    Time frame: 1 month

  5. Combined clinical endpoint (death, stroke, recurrent TTS, heart failure, acute coronary syndrome, atrial fibrillation

    Combined clinical endpoint

    Time frame: 1 year

  6. Individual endpoints of the combined clinical endpoint Occurrence of death, stroke, recurrent TT, heart failure, acute coronary syndrome, atrial fibrillation will be analyzed and compared individually

    Individual clinical endpoints Occurrence of death, stroke, recurrent TT, heart failure, acute coronary syndrome, atrial fibrillation will be analyzed and compared individually in the 2 groups

    Time frame: 1 year

  7. Angina and quality of life status during daily life assessed in routine clinical practice

    Evaluated in clinical visits

    Time frame: 1 year

Other outcomes

  1. Cardiac Magnetic Resonance (CMR)

    CMR to detect edema, late gadolinium enhancement to correlate with clinical data and prognosis

    Time frame: 1 year

  2. ECG

    Correlation of ECG findings with clinical features and prognosis Different ECG parameters will be correlated with the echocardiographic and clinical outcome measures to detect potential correlations

    Time frame: 1 year

  3. Pharmacogenetic substudy

    To assess pharmacogenetic implications of different beta-blockers used The pharcacogenetics of the 2 different betablockers used in this study will be studied in relation to the main echocardiographic and clinical endpoints

    Time frame: 1 year

  4. Coronary angiography

    To assess correlation with angiographic features and clinical findings and prognosis

    Time frame: 1 year

  5. Biomarkers, inflammatory data, mRNAs

    Association with clinical findings and prognosis

    Time frame: 1 year

07

Study locations

1 site
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
    • Fernando Alfonso, MD · Contactfalf@hotmail.com · 34 680483165
    • Fernando Alfonso, MD · Principal investigator
    • Jorge Salamanca, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data will be considered to be shared by the PI and steering committee, upon adequate and justified request, within a defined scientific research project, and providing adequate supervision of the analysis and credit to the original inverstigators is prearranged

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: 1 year after publication of the main combined clinical endpoint

Access criteria: to be defined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Dec 2025, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 19, 2024
StartEst.
Aug 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06509074
Lead sponsor
Spanish Society of Cardiology
Collaborators
Hospital Universitario de La Princesa (Madrid, Spain)
Responsible party
Fernando Alfonso (Head Cardiac Department, Spanish Society of Cardiology) — Principal investigator
First posted
Jul 19, 2024
Start date
Aug 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 26, 2024

Study contacts

Fernando Alfonso, MD
Contact
falf@hotmail.com
34 680483165
Fernando Alfonso, MD
study chair · Hospital Universitario La Princesa, Madrid. IIS-IP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beta blockers

Start the discussion